Exagen Inc. Common Stock (XGN) is a publicly traded Healthcare sector company. As of May 21, 2026, XGN trades at $3.83 with a market cap of $84.32M and a P/E ratio of -4.24. XGN moved +2.95% today. Year to date, XGN is -35.63%; over the trailing twelve months it is -35.74%. Its 52-week range spans $2.38 to $12.23. Analyst consensus is strong buy with an average price target of $8.67. Rallies surfaces XGN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Exagen Reports Record Q1 2026 Revenue, Unveils Strategic Growth Plans: Exagen Inc delivered record Q1 2026 revenue, marking its highest quarterly sales to date, driven by increased adoption of its autoimmune diagnostics portfolio. Management outlined strategic growth plans including expanded commercial partnerships and advancement of its proprietary testing pipeline.
| Metric | Value |
|---|---|
| Price | $3.83 |
| Market Cap | $84.32M |
| P/E Ratio | -4.24 |
| EPS | $-0.89 |
| Dividend Yield | 0.00% |
| 52-Week High | $12.23 |
| 52-Week Low | $2.38 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $68.38M |
| Net Income | $-20.17M |
| Gross Margin | 58.32% |
7 analysts cover XGN: 0 strong buy, 7 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $8.67.